FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2396116581> ?p ?o ?g. }

• W2396116581 endingPage "e0153052" @default.
• W2396116581 startingPage "e0153052" @default.
• W2396116581 abstract "To compare the effectiveness of bevacizumab and ranibizumab in the treatment of exudative age-related macular degeneration (AMD).Multicentre, randomized, controlled, double-masked clinical trial in 327 patients. The non-inferiority margin was 4 letters.Patients ≥ 60 years of age with primary or recurrent sub- or juxtafoveal choroidal neovascularization (CNV) secondary to AMD with a total area of CNV < 12 disc areas and a best corrected visual acuity (BCVA) score between 20 and 78 letters on an EDTRS like chart in the study eye.Monthly intravitreal injections with 1.25 mg bevacizumab or 0.5 mg ranibizumab were given during one year. Intention to treat with last observation carried forward analysis was performed.Primary outcome was the change in BCVA in the study eye from baseline to 12 months.The mean gain in BCVA was 5.1 (±14.1) letters in the bevacizumab group (n = 161) and 6.4 (±12.2) letters in the ranibizumab group (n = 166) (p = 0.37). The lower limit of the 95% confidence interval of the difference in BCVA gain was 3.72. The response to bevacizumab was more varied; 24% of patients showed a gain of ≥15 letters, 11% a loss of ≥15 letters and 65% a gain or loss < 15 letters compared to 19%, 5% and 76% respectively for ranibizumab (p = 0.038). No significant differences in absolute CRT and CRT change (p = 0.13) or in the presence of subretinal or intraretinal fluid (p = 0.14 and 0.10, respectively) were observed. However, the presence of any fluid on SD-OCT (subretinal and/or intraretinal) differed significantly (p = 0.020), with definite fluid on SD-OCT in 45% of the patients for bevacizumab versus 31% for ranibizumab. The occurrence of serious adverse events and adverse events was similar, with 34 SAEs and 256 AEs in the bevacizumab group and 37 SAEs and 299 AEs in the ranibizumab group (p = 0.87 and p = 0.48, respectively).Bevacizumab was not inferior to ranibizumab. The response to bevacizumab was more varied with higher percentages of both gainers and losers and more frequently observed retinal fluid on SD-OCT at 12 months when compared to the ranibizumab group.Trialregister.nl NTR1704." @default.
• W2396116581 created "2016-06-24" @default.
• W2396116581 creator A5018227698 @default.
• W2396116581 creator A5031015752 @default.
• W2396116581 creator A5033513947 @default.
• W2396116581 creator A5052961001 @default.
• W2396116581 creator A5059343622 @default.
• W2396116581 creator A5059883802 @default.
• W2396116581 creator A5073214161 @default.
• W2396116581 creator A5084817085 @default.
• W2396116581 creator A5086926273 @default.
• W2396116581 date "2016-05-20" @default.
• W2396116581 modified "2023-10-14" @default.
• W2396116581 title "Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study" @default.
• W2396116581 cites W1481978003 @default.
• W2396116581 cites W1500728559 @default.
• W2396116581 cites W2000366267 @default.
• W2396116581 cites W2003158462 @default.
• W2396116581 cites W2034029819 @default.
• W2396116581 cites W2053567993 @default.
• W2396116581 cites W2059547624 @default.
• W2396116581 cites W2073559780 @default.
• W2396116581 cites W2081930185 @default.
• W2396116581 cites W2118551928 @default.
• W2396116581 cites W2121558500 @default.
• W2396116581 cites W2124415048 @default.
• W2396116581 cites W2131192872 @default.
• W2396116581 cites W2142693543 @default.
• W2396116581 cites W2146673937 @default.
• W2396116581 cites W2154073405 @default.
• W2396116581 cites W2165062842 @default.
• W2396116581 cites W2738996050 @default.
• W2396116581 cites W4245313820 @default.
• W2396116581 doi "https://doi.org/10.1371/journal.pone.0153052" @default.
• W2396116581 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4874598" @default.
• W2396116581 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27203434" @default.
• W2396116581 hasPublicationYear "2016" @default.
• W2396116581 type Work @default.
• W2396116581 sameAs 2396116581 @default.
• W2396116581 citedByCount "51" @default.
• W2396116581 countsByYear W23961165812016 @default.
• W2396116581 countsByYear W23961165812017 @default.
• W2396116581 countsByYear W23961165812018 @default.
• W2396116581 countsByYear W23961165812019 @default.
• W2396116581 countsByYear W23961165812020 @default.
• W2396116581 countsByYear W23961165812021 @default.
• W2396116581 countsByYear W23961165812022 @default.
• W2396116581 countsByYear W23961165812023 @default.
• W2396116581 crossrefType "journal-article" @default.
• W2396116581 hasAuthorship W2396116581A5018227698 @default.
• W2396116581 hasAuthorship W2396116581A5031015752 @default.
• W2396116581 hasAuthorship W2396116581A5033513947 @default.
• W2396116581 hasAuthorship W2396116581A5052961001 @default.
• W2396116581 hasAuthorship W2396116581A5059343622 @default.
• W2396116581 hasAuthorship W2396116581A5059883802 @default.
• W2396116581 hasAuthorship W2396116581A5073214161 @default.
• W2396116581 hasAuthorship W2396116581A5084817085 @default.
• W2396116581 hasAuthorship W2396116581A5086926273 @default.
• W2396116581 hasBestOaLocation W23961165811 @default.
• W2396116581 hasConcept C118487528 @default.
• W2396116581 hasConcept C126322002 @default.
• W2396116581 hasConcept C141071460 @default.
• W2396116581 hasConcept C168563851 @default.
• W2396116581 hasConcept C2776403814 @default.
• W2396116581 hasConcept C2776694085 @default.
• W2396116581 hasConcept C2777802072 @default.
• W2396116581 hasConcept C2778257484 @default.
• W2396116581 hasConcept C2781100027 @default.
• W2396116581 hasConcept C2781359195 @default.
• W2396116581 hasConcept C44249647 @default.
• W2396116581 hasConcept C71924100 @default.
• W2396116581 hasConceptScore W2396116581C118487528 @default.
• W2396116581 hasConceptScore W2396116581C126322002 @default.
• W2396116581 hasConceptScore W2396116581C141071460 @default.
• W2396116581 hasConceptScore W2396116581C168563851 @default.
• W2396116581 hasConceptScore W2396116581C2776403814 @default.
• W2396116581 hasConceptScore W2396116581C2776694085 @default.
• W2396116581 hasConceptScore W2396116581C2777802072 @default.
• W2396116581 hasConceptScore W2396116581C2778257484 @default.
• W2396116581 hasConceptScore W2396116581C2781100027 @default.
• W2396116581 hasConceptScore W2396116581C2781359195 @default.
• W2396116581 hasConceptScore W2396116581C44249647 @default.
• W2396116581 hasConceptScore W2396116581C71924100 @default.
• W2396116581 hasFunder F4320321007 @default.
• W2396116581 hasIssue "5" @default.
• W2396116581 hasLocation W23961165811 @default.
• W2396116581 hasLocation W239611658110 @default.
• W2396116581 hasLocation W239611658111 @default.
• W2396116581 hasLocation W239611658112 @default.
• W2396116581 hasLocation W239611658113 @default.
• W2396116581 hasLocation W239611658114 @default.
• W2396116581 hasLocation W23961165812 @default.
• W2396116581 hasLocation W23961165813 @default.
• W2396116581 hasLocation W23961165814 @default.
• W2396116581 hasLocation W23961165815 @default.
• W2396116581 hasLocation W23961165816 @default.
• W2396116581 hasLocation W23961165817 @default.
• W2396116581 hasLocation W23961165818 @default.

• next